The global CAR-T cell therapy market size reached USD 1.29 Billion in 2021 and is expected to register a revenue CAGR of 24.9% during the forecast period, according to latest analysis by Emergen Research. Increasing prevalence of cancer across the globe and rising mortality rate from cancer are expected to drive the global CAR-T cell therapy market revenue growth over the forecast period. Rapidly expanding clinical trial activities, proliferating mergers & acquisitions, and attractive initial public offerings are contributing to revenue growth of the global CAR T-cell therapy market.
Rapidly expanding clinical trial activities, proliferating mergers & acquisitions, and attractive initial public offerings are contributing to revenue growth of the global CAR T-cell therapy market. Consistent research on cancer and its treatment, as well as advances in medicines, further support the expansion of the market.
To learn more details about the Global CAR-T Cell Therapy Market report, visit @ https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
Some major companies in the global market report include Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
The report closely studies the growth trajectory of the global CAR-T Cell Therapy market. It brings to light the global dominance of the leading regional segments, including North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.
The COVID-19 pandemic had an adverse effect on the expansion of the global CAR T-cell therapy market as a result of the lockdown that disrupted the distribution of cancer medications throughout the world. The travel restrictions halted commercial operations and biopharmaceutical and life sciences industries experienced supply chain interruptions as they awaited the availability of new batches of raw materials for CAR T-cell manufacture.
Emergen Research has segmented the global CAR-T cells therapy market on the basis of type, indication, end-use, and region:
- Type Outlook (Revenue, USD Billion; 2019-2030)
- Indication Outlook (Revenue, USD Billion; 2019-2030)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphoblastic Leukemia (CLL)
- Multiple Myeloma (MM)
- Follicular Lymphoma (FL)
- End-Use Outlook (Revenue, USD Billion; 2019-2030)
- Cancer Treatment Centers
The multiple myeloma segment accounted for a significant revenue share in 2021. CAR T-cell therapy is a promising treatment for people with relapsed or refractory multiple myeloma who have not responded to prior medications. It is a highly specialized treatment that involves genetically modifying a patient’s T cells in order to eliminate their multiple myeloma by targeting B-cell maturation antigen (BCMA).
Thank you for reading our report. If you have any requests for customization of the latest report, kindly get in touch with us. Our team will assist you and ensure the report is designed as per your requirements.
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyses consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.